Eventide Asset Management, LLC 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-23 10:28 am Unchanged | 2024-12-31 | 13G | INOZYME PHARMA INC INZY | Eventide Asset Management, LLC | 2,220,000 3.460% | 0 (Unchanged) | Filing |
| 2025-02-14 12:01 pm Sale | 2024-12-31 | 13G | INOZYME PHARMA INC INZY | Eventide Asset Management, LLC | 2,220,000 3.460% | -1,225,363 (-35.57%) | Filing |
| 2024-11-14 12:19 pm Purchase | 2024-09-30 | 13G | INOZYME PHARMA INC INZY | Eventide Asset Management, LLC | 4,134,436 6.440% | 954,599 (+30.02%) | Filing |
| 2024-02-14 11:54 am Purchase | 2023-12-31 | 13G | INOZYME PHARMA INC INZY | Eventide Asset Management, LLC | 3,179,837 5.150% | 3,179,837 (New Position) | Filing |